Drugs FDA-approved for hematology / oncology in 2020: ‘Game-changing’ and ‘niche’ indications
Blood & Cancer
English - June 18, 2020 08:00 - 29 minutes - 46.1 MB - ★★★★★ - 31 ratingsMedicine Health & Fitness Science Life Sciences oncologists radiotherapy cancer chemotherapy doctors healthcare hematologists hematology immunotherapy marrow Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
The Food and Drug Administration has approved dozens of drugs for new hematology/oncology indications this year. Host David Henry, MD, was joined by David Mintzer, MD, and other colleagues at Penn Medicine in Philadelphia – Justine Cohen, DO, and Ingrid Kohut, DO – to discuss some of these approvals.
Dr. Mintzer reviewed:
The “game-changing” approval of niraparib (Zejula) in advanced ovarian, fallopian tube, or primary peritoneal cancer. The “exciting” approval of sacituzumab govitecan-hziy (Trodelvy) in metastatic triple-negative breast cancer. The “COVID-relevant” approval of a new dosing regimen for pembrolizumab (Keytruda) – 400 mg every 6 weeks – across all approved adult indications. The “niche” approval of mitomycin (Jelmyto) for adults with low-grade upper tract urothelial cancer. And several other approvals the FDA granted this year.Details on all approvals are available on the FDA website.
* * *
Disclosures:
Dr. Henry and all guests reported having no relevant disclosures.
* * *
For more MDedge Podcasts, go to mdedge.com/podcasts
Email the show: [email protected]
Interact with us on Twitter: @MDedgehemonc
David Henry on Twitter: @davidhenrymd